Financials

v3.21.2
CONDENSED BALANCE SHEETS - USD ($)
$ in Thousands
Jun. 30, 2021
Dec. 31, 2020
Current assets:    
Cash and cash equivalents $ 9,680 $ 5,413
Receivables 103 884
Inventory 129 328
Prepaid expenses and other current assets 648 522
Discontinued operations - current assets 70 181
Total current assets 10,630 7,328
Property and equipment, net 524 618
Operating lease right-of-use asset 353 141
Total assets 11,507 8,087
Current liabilities:    
Accounts payable 439 1,253
Accrued clinical trials expenses 38 214
Other accrued liabilities 304 319
Operating lease liability, current 108 150
Current portion of long-term debt 0 327
Discontinued operations - current liabilities 1,627 1,960
Total current liabilities 2,516 4,223
Operating lease liability, noncurrent 244 0
Long-term debt 0 332
Total liabilities 2,760 4,555
Stockholders' equity:    
Common stock, at amounts paid-in 10 7
Additional paid-in capital 380,337 370,804
Accumulated deficit (371,600) (367,279)
Total stockholders' equity 8,747 3,532
Total liabilities and stockholders' equity $ 11,507 $ 8,087

Source

v3.21.2
CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2021
Jun. 30, 2020
Jun. 30, 2021
Jun. 30, 2020
Revenues:        
Total revenues $ 445 $ 1,249 $ 1,127 $ 2,375
Operating expenses:        
Cost of goods sold 89 0 199 0
Research and development 1,646 1,644 3,523 3,456
Selling, general and administrative 1,035 1,223 2,362 2,511
Total operating expenses 2,770 2,867 6,084 5,967
Loss from operations (2,325) (1,618) (4,957) (3,592)
Other income (expense):        
Interest expense, net 0 (250) (2) (472)
Non-cash loss on changes in the fair value of warrants 0 0 0 (923)
Gain on debt extinguishment 661 0 661 0
Other expense, net (16) (7) (23) (220)
Other income (expense), net 645 (257) 636 (1,615)
Loss from continuing operations (1,680) (1,875) (4,321) (5,207)
Loss from discontinued operations 0 (2,766) 0 (5,018)
Net loss and comprehensive loss $ (1,680) $ (4,641) $ (4,321) $ (10,225)
Basic and diluted net loss per common share from continuing operations $ (0.17) $ (0.59) $ (0.45) $ (1.76)
Basic and diluted net loss per common share from discontinued operations $ 0 $ (0.87) $ 0 $ (1.70)
Weighted average shares used in computing basic and diluted net loss per common share 9,864 3,165 9,578 2,960
License revenue        
Revenues:        
Total revenues $ 3 $ 6 $ 5 $ 6
Product revenue        
Revenues:        
Total revenues 89 39 200 39
Grant revenue        
Revenues:        
Total revenues $ 353 $ 1,204 $ 922 $ 2,330

Source

v3.21.2
CONDENSED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
6 Months Ended
Jun. 30, 2021
Jun. 30, 2020
Cash flows from operating activities:    
Net loss $ (4,321) $ (10,225)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 112 128
Non-cash interest expense 2 296
Non-cash loss on changes in fair value of warrants 0 923
Non-cash gain on debt extinguishment (661) 0
Stock-based compensation 695 (5)
Finance costs attributable to issuance of warrants 0 211
Other (10) (6)
Changes in operating assets and liabilities:    
Receivables 781 (68)
Inventory 199 29
Prepaid expenses and other assets (15) (68)
Accounts payable (1,079) 127
Accrued sales allowances (60) (745)
Other accrued liabilities (199) 208
Net cash used in operating activities (4,556) (9,195)
Cash flows from investing activities:    
Purchases of property and equipment (18) (87)
Net cash used in investing activities (18) (87)
Cash flows from financing activities:    
Net proceeds from equity offering 8,841 1,895
Net proceeds from the exercises of common stock warrants 0 7,008
Net loan proceeds 0 654
Net cash provided by financing activities 8,841 9,557
Net increase in cash and cash equivalents 4,267 275
Cash and cash equivalents at beginning of period 5,413 5,223
Cash and cash equivalents at end of period 9,680 5,498
Supplemental disclosure of cash flow information:    
Interest paid $ 0 $ 198

Source